These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29995632)

  • 1. Sequential measurements of IGF-I serum concentrations in adolescents with Laron syndrome treated with recombinant human IGF-I (rhIGF-I).
    Breil T; Kneppo C; Bettendorf M; ; Müller HL; Kapelari K; Schnabel D; Woelfle J
    J Pediatr Endocrinol Metab; 2018 Aug; 31(8):895-902. PubMed ID: 29995632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome.
    Bang P; Woelfle J; Perrot V; Sert C; Polak M
    Eur J Endocrinol; 2021 Feb; 184(2):267-276. PubMed ID: 33434161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
    Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
    J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
    Tonella P; Flück CE; Mullis PE
    Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
    Chernausek SD; Backeljauw PF; Frane J; Kuntze J; Underwood LE;
    J Clin Endocrinol Metab; 2007 Mar; 92(3):902-10. PubMed ID: 17192294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with recombinant insulin-like growth factor 1 (IGF-1) in a child with IGF-1 gene mutation.
    Concolino D; Muzzi G; Sestito S; Vega G; Bonapace G; Strisciuglio P
    Eur J Pediatr; 2010 Feb; 169(2):245-7. PubMed ID: 19517134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype.
    Azcona C; Preece MA; Rose SJ; Fraser N; Rappaport R; Ranke MB; Savage MO
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):787-92. PubMed ID: 10619985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in plasma amino acids metabolites, caused by long-term IGF-I deficiency, are reversed by IGF-I treatment - A pilot study.
    Barazani C; Werner H; Laron Z
    Growth Horm IGF Res; 2020 Jun; 52():101312. PubMed ID: 32200226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
    Woods KA; Camacho-Hübner C; Bergman RN; Barter D; Clark AJ; Savage MO
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1407-11. PubMed ID: 10770174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of hypoglycemia in response to varying doses of recombinant human insulin-like growth factor-I (rhIGF-I) in children and adolescents with low serum concentrations of IGF-I.
    Guevara-Aguirre J; Guevara-Aguirre M; Rosenbloom AL
    Acta Paediatr; 2006 Feb; 95(2):199-202. PubMed ID: 16449027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant IGF-I: Past, present and future.
    Bright GM
    Growth Horm IGF Res; 2016 Jun; 28():62-5. PubMed ID: 26822565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human insulin-like growth factor I (IGF-I): risks and benefits of normalizing blood IGF-I concentrations.
    Clark RG
    Horm Res; 2004; 62 Suppl 1():93-100. PubMed ID: 15761240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Human Insulin-Like Growth Factor-1 Treatment of Severe Growth Failure in Three Siblings with STAT5B Deficiency.
    Muthuvel G; Al Remeithi SS; Foley C; Dauber A; Hwa V; Backeljauw P
    Horm Res Paediatr; 2024; 97(2):195-202. PubMed ID: 37586336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term auxological and pubertal outcome of patients with hereditary insulin-like growth factor-I deficiency (Laron and growth hormone-gene deletion syndrome) treated with recombinant human insulin-like growth factor-I.
    Messina MF; Arrigo T; Valenzise M; Ghizzoni L; Caruso-Nicoletti M; Zucchini S; Chiabotto P; Crisafulli G; Zirilli G; De Luca F
    J Endocrinol Invest; 2011 Apr; 34(4):292-5. PubMed ID: 20543555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adult and near-adult height in patients with severe insulin-like growth factor-I deficiency after long-term therapy with recombinant human insulin-like growth factor-I.
    Backeljauw PF; Kuntze J; Frane J; Calikoglu AS; Chernausek SD
    Horm Res Paediatr; 2013; 80(1):47-56. PubMed ID: 23887143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pubertal Timing and Growth Dynamics in Children With Severe Primary IGF-1 Deficiency: Results From the European Increlex
    Bang P; Polak M; Perrot V; Sert C; Shaikh H; Woelfle J
    Front Endocrinol (Lausanne); 2022; 13():812568. PubMed ID: 35250870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation - first three years of Polish experience.
    Petriczko E; Jackowski T; Horodnicka-Józwa A; Wikiera B; Noczyńska A; Korpal-Szczyrska M; Birkholz-Walerzak D; Małecka-Tendera E; Kalina-Fraska B; Kalina M; Barg E; Beń-Skowronek I; Szewczyk L; Hilczer M; Smyczyńska J; Stawerska R; Lewiński A; Ziora K; Bossowski A; Pietrewicz E; Pyrżak B; Kędzia A; Szalecki M; Kilian A; Walczak M
    Endokrynol Pol; 2019; 70(1):20-27. PubMed ID: 30351442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans.
    Lieberman SA; Bukar J; Chen SA; Celniker AC; Compton PG; Cook J; Albu J; Perlman AJ; Hoffman AR
    J Clin Endocrinol Metab; 1992 Jul; 75(1):30-6. PubMed ID: 1377706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.